Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SRA-444 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| SRA-444 + Placebo | EXPERIMENTAL | Experimental; Placebo |
| Name | Type | Description |
|---|---|---|
| SRA-444 | DRUG | - |
Inclusion criteria: * Men or women from 60 years of age at screening. * Healthy as determined by the investigator on the basis of medical history, physical examination, clinical laboratory test results, vital signs, and 12-lead electrocardiogram (ECG). Exclusion criteria: * History of drug abuse ...
Top 20 of 24 competitors
SRA-444 is an investigational small molecule being developed by Pfizer for Alzheimer's disease. It is currently in Phase 1 clinical development, meaning it has not been approved and is still being studied for safety and tolerability in early-stage trials.
SRA-444 is being developed by Pfizer, Inc. (NYSE: PFE). The company is conducting Phase 1 clinical trials to evaluate the drug's safety, tolerability, and pharmacokinetics in healthy volunteers.
SRA-444 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Two Phase 1 trials have been completed, but the drug remains in early-stage clinical testing.
SRA-444 has been studied in two completed Phase 1 trials: NCT00452504, a single ascending dose study in healthy subjects in the Netherlands, and NCT00499200, a study evaluating safety, tolerability, pharmacokinetics, and 5-HT1A receptor occupancy in healthy volunteers in Sweden.
No alternative names for SRA-444 have been disclosed. The drug is identified by its code name SRA-444 in clinical trial registries and is being developed solely by Pfizer for Alzheimer's disease.